About
Synthetic Nucleotides
Areas of Focus
Categories
Small Molecule Pharmaceutical
Clinical Trials (4)
View allTotal Trials
4
As Lead Sponsor
4
As Collaborator
0
Total Enrollment
243
By Phase
PHASE1: 2PHASE3: 1PHASE2: 1
By Status
COMPLETED: 3TERMINATED: 1
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
Today
Hover over trial bars to see details
Recent Trials
NCT02406833Lead Sponsor
Phase I Dose Escalation Study to Investigate the Safety of ISTH0036 in Subjects With Glaucoma Undergoing Trabeculectomy
PHASE1Completed
13 participants
Started: Apr 30, 2015 · Completed: Aug 31, 2017
NCT00761280Lead Sponsor
Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma
PHASE3Terminated
27 participants
Started: Dec 31, 2008 · Completed: Jun 30, 2012
NCT00844064Lead Sponsor
Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2
PHASE1Completed
62 participants
Started: Jan 31, 2005 · Completed: Nov 30, 2011
NCT00431561Lead Sponsor
Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma
PHASE2Completed
141 participants
Started: Apr 30, 2003 · Completed: Mar 31, 2009
Locations (1)
Headquarters
Munich, Germany
Map
Loading map...